Share this article on:


Can, F. Kamit1; Anil, A.B.1; Göç, Z.1; Anil, M.2; Alparslan, C.1; Elmas, O. Cebeci1; Bal, A.3; Gokalp, G.3

Pediatric Critical Care Medicine: May 2014 - Volume 15 - Issue 4_suppl - p 7
doi: 10.1097/01.pcc.0000448742.09517.18
Abstracts of the 7th World Congress on Pediatric Critical Care

1pediatric intensive care unit, Izmir Tepecik Research and Training Hospital, Izmir, Turkey 2pediatric emergency, Izmir Tepecik Research and Training Hospital, Izmir, Turkey 3pediatric emergency department, Izmir Tepecik Research and Training Hospital, Izmir, Turkey

Background and aims: High-flow nasal cannula (HFNC) therapy is a treatment for respiratory distress in neonates and children.

Aims: The aim the study was to assess the effectiveness of HFCN therapy in a pediatric intensive care unit (PICU).

Methods: In this observational study, we included all consecutive patients from 1 month to 18 years of age who were admitted to the PICU in Tepecik Teaching and Research Hospital, Izmir, Turkey and treated with a high-flow nasal cannula between October 1, 2013, and December 31, 2013. The vital parameters, respiratory clinical score (RCS), The Brussels Sedation Scale (BSS) and sPO2/FiO2 ratio were evaluated.

Results: A total of 19 patients (median age: 48 month; 1–180 months; male/female: 12/7) were included the study. The indication for HFNC were postextubation (6 cases), asthma (5), bronchiolitis (2), pneumonia (2), pulmonary edema (2), croup syndrome (1), extrapulmonary acute lung injury (1). There were significant improvements in the oxygene saturation, pulse rate, respiratory rate, RCS, BSS and sPO2/FiO2 ratio.

Conclusions: The HFCN therapy improves the respiratory parameters and sedation scale in pediatric respiratory distress syndrome. HFCN treatment carries an important role in PICU.

©2014The Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies